戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 perimental annotations of intrinsic disorder are available for 0.1% of 147 000 000 of currently seque
2                                 Outcome data was available for 1,165 women, 6.7% of whom had sPTB, 16
3                Follow-up measures of linkage were available for 1,128 (77%) and BP for 1,106 (76%).
4                                Complete data were available for 1,165 participants.
5 nd Main Results: Genome-wide genotyping data were available for 1,699 individuals with ILAs and 10,27
6 ed the voucher, and follow-up data at 1 year were available for 10 802 patients (98.2%).
7                                Methods: Data were available for 10 patients with neuroendocrine tumor
8                                         Data were available for 100 subjects with severe asthma (medi
9 tile range, 19 to 21), and data on mortality were available for 100% of participants.
10                                         Data were available for 1001 individuals of white European an
11                               Follow-up data were available for 1014 patients who were included in th
12        Complete VA deterioration information was available for 1020 patients, and complete informatio
13   Outcome data at 1 year after spinal injury were available for 1031 patients (66.6%).
14                                      Ct data were available for 106 (71%) of 150 enrolled index patie
15                         Primary outcome data were available for 1072 patients in the intensive group
16 ng with repeat testing after return to shore was available for 120 of the 122 persons on board over a
17                               Follow-up data were available for 125 eyes of 70 patients.
18                      Pathologic confirmation was available for 143 nodules (122 HCCs, 18 non-HCC mali
19                         Primary outcome data were available for 1692 infants (92.8%).
20                       At 12 months, OSS data were available for 189 (94%) of 201 participants assigne
21 ents and on death from cardiovascular causes were available for 203 (95%) and 214 (100%), respectivel
22                  Data on the primary outcome were available for 206 women (81%).
23                                         Data were available for 214 patients for the primary analysis
24 mal baseline EF, information on follow-up EF was available for 216, of whom 90 (42%) recovered their
25                                 Outcome data were available for 2391 (97.7%) participants, and 6% (14
26  measures (with a mean follow-up of 6 years) were available for 242 mutation carriers and 262 non-car
27   Structural magnetic resonance imaging data were available for 250 participants.
28 entified reviews and malpractice claims data were available for 264 surgeons from 2000 to 2015.
29          PET/CT scans and pathology findings were available for 270 N0 neck sides from 212 participan
30          Of 1046 eligible eyes, 10-year data were available for 293 (28%), which were included in the
31                                         Data were available for 305 pwMND (mean age at diagnosis=62.2
32                         Primary outcome data were available for 306 (85%) of 362 participants allocat
33                          Breast milk samples were available for 31 LOD cases (8 serotype Ia and 23 se
34                   Visual acuity measurements were available for 3240 (95.3%) participants.
35 bitual coffee intake and relevant covariates were available for 347,077 individuals in the UK Biobank
36 T, and aHCV measurements at 0.6 to 4.1 years were available for 35% to 63% of the sample.
37                                 PD-L1 status was available for 36 patients; 15 (42%) had >= 1% expres
38          Complete outcome and covariate data were available for 4,428 and 4,369 participants at ages
39 mic regions involved in isoniazid resistance were available for 4,563 patients.
40                       4-month follow-up data were available for 406 (64%) participants, 25 were lost
41                              Biannual series were available for 422 eyes of 214 participants.
42                                         Data were available for 455 state-years from 48 states, inclu
43 018, complete data for the primary endpoints were available for 474 (97%) individuals.
44                                         Data was available for 516, 424 and 455 patients at baseline,
45              Genetic and structural MRI data were available for 516 healthy non-Hispanic Caucasian un
46                            Ventilation rates were available for 52 events (47 patients).
47                          Abdominal CT or MRI was available for 53 of 90 patients.
48                                Baseline data were available for 593 women in the intervention (93.3%
49    Toxicokinetic or pharmacokinetic analysis was available for 61 patients (13 chloroquine, three hyd
50                        Five-year photographs were available for 615/862 (71%) eligible patients.
51        Research and development expenditures were available for 63 (18%) products, developed by 47 di
52                                         Data were available for 75,839 individuals prescribed PrEP, a
53    Of the 804 PACG patients, genotyping data were available for 768 individuals and included 436 with
54 n Results: NO(2) exposures at birth or age 6 were available for 777 children with one or more CC16 me
55  4.6+/-2.9%), clinical follow-up information was available for 778 (98%) patients.
56                    15-20 year follow-up data was available for 79 (41 Nissen, 38 anterior).
57                            In contrast, data were available for 79% of eligible articles, highlightin
58 ents were included, of whom seizure outcomes were available for 8191 (89.5%) participants at 2 years,
59                         Primary outcome data was available for 88% (rosuvastatin n = 20, control n =
60                             Vaccination data were available for 91 (83%) cases; 51 (56%) had 2 RV1 do
61 otic administration, and signs of infection) were available for 98.7% randomized to the probiotic gro
62                                Fracture data were available for 9802 of the 9803 participants.
63                      Complete follow-up data were available for 99.2% of the neonates.
64  27) in the control group; data on mortality were available for 99.9% of patients in the study.
65 d complete information on late complications was available for 991 patients.
66  we show that, if time-resolved measurements are available for a number of overlapping peptides that
67                           This technique has been available for a decade, yet the current state and s
68  CO(2) flux have been biased by observations being available for a relatively small number of accessi
69                                Survival data was available for a subset of patients.
70 tes for each lag when at least three studies were available for a specific lag.
71     Additional pathological comparisons that were available for a subset in ADNI suggested that subty
72 , and digested grains, only a small fraction was available for absorption in the gut, with amounts va
73               Few or no effective treatments are available for ageing-related neurodegenerative disea
74                         Primary outcome data were available for all 593 patients.
75                          Live birth outcomes were available for all couples, and 1629 men (69%) had s
76                   No global burden estimates are available for ALRIs associated with human metapneumo
77                Of 160 patients enrolled, 149 were available for analyses.
78 ics), where limited amounts of glycoproteins are available for analysis.
79                   Further data releases will be available for analysis as recruitment at the VA conti
80  of genetically engineered material that may be available for analysis.
81                Forty-nine patients/130 sites were available for analysis at T2 whereas 44 patients/12
82                                Clinical data were available for analysis from 38 patients, including
83                              Dietary surveys were available for analysis from 614 (77%), and 561 (71%
84                                  Serial data were available for analysis from 70 patients (LLL <0.5 m
85  categories: <5, 5-10, >10 kg; 1033 patients were available for analysis.
86 nts (aspirin n = 83,529, control n = 81,973) were available for analysis.
87 yes) of 314 patients (88.5% of 355 patients) were available for analysis.
88                    Samples from 135 patients were available for analysis.
89 After inclusion/exclusion criteria, 316 eyes were available for analysis; 131 eyes had MMC delivered
90 ometric holes in the photonic circuit, which are available for analyte detection with high efficiency
91                        Yet, hitherto no tool was available for analyzing the quality of, subsampling,
92     No specific medical or genetic therapies are available for any type of EDS.
93 use of the extensive genome information that is available for Arabidopsis thaliana and measure how ma
94                           Very few PA values are available for basic organic monoradicals and none fo
95                      However, no information is available for bovine CYP3A (bCYP3A).
96 Water quality guidance values for Legionella are available for building managers but are generally no
97                        While many techniques are available for characterization of pure, homogeneous
98 autoimmune disorders, but no TLR7 antagonist is available for clinical use to date.
99 esearch site where multidecadal measurements are available for comparison, we show that if turnover i
100                            A total of 29 VTs were available for comparison.
101 panding policy scope requires more land than is available for compensation activities.
102                              Forty-five ECGs were available for corrected QT interval (QTc) measureme
103  strategies for the Smith-Waterman algorithm are available for CPUs.
104 Currently no integrated and guided procedure is available for data preparation and subsequent interpr
105 robes for intracellular calcium imaging have been available for decades, the development of probes fo
106                             Although methods are available for deuterium incorporation at both early
107                      No clinical blood tests are available for diagnosis or disease monitoring.
108 analysis is data availability, as fewer data are available for diversion programs than for more estab
109 heir uncertainties for eastern US NEON sites are available for download, and are being expanded to th
110  possible; because they are exothermic, heat is available for downstream protein processing; because
111 cularly when only a few visual field results are available for each eye.
112             Currently, no curative treatment is available for early-to-intermediate stage HCC, charac
113 zwitterionic/cationic PFAS molecules in vivo are available for enzymatic degradation.
114                     Currently, no approaches are available for evaluating the resolving capability of
115                             The g-iELISA kit is available for evaluation in reference laboratories in
116  useful when only a limited amount of sample is available, for example, polyolefin film layers or the
117 nterfaces to domain experts, limited support is available for figure display, project management, and
118 e for VOD/SOS diagnosis, where detailed data were available for final analysis.
119              Hence, additional Zr sites must be available for formate formation.
120 arrying insertions for vitamin pathway genes are available for free, public distribution via the Maiz
121 nt in theranostics, a variety of new targets are available for further clinical investigation.
122  19 patients at PUH and other UPMC hospitals were available for further analysis, including whole-gen
123                             Several programs are available for gene finding, yet it is currently uncl
124 ontext of the partner; (iii) since more data are available for general protein-protein interactions,
125                       Limited treatment data are available for hepatitis C virus (HCV) in sub-Saharan
126 mensional genomics and epigenomics data that are available for hundreds of cell types, this model ena
127              Tools based on clinical factors are available for identifying patients at risk, but only
128 rnaria challenge, suggesting that more IL-33 was available for ILC2 activation and that a COX product
129 ffer a novel form of CAR-T-cell product that is available for immediate clinical use, thereby broaden
130 ens following chemotherapy from 192 patients were available for immunohistochemical analysis.
131                                       PINCER is available for individual gene knockout and genome-wid
132                       Structural information is available for individual P domains from different par
133            Diverse wheat germplasm resources are available for industrial production and breeding sel
134      Nevertheless, no structural information is available for inhibitors bound to human CRM1 ((Hs)CRM
135  whole body autopsy reports and brain tissue were available for interrogation was established.
136                          Although structures are available for isolated ClpX and ClpP rings, it remai
137                      Many effective vaccines are available for JE, and the use of a recently develope
138 evolutionary selection if reliable estimates are available for key background parameters and ten or m
139                                Few estimates were available for later stages of the treatment cascade
140 However, since limited analytical approaches are available for longitudinal traits, these data are of
141 city of the state-of-the-art techniques that are available for mammalian cells.
142             Although high-throughput methods are available for mapping brain-wide activity and transc
143 ains unclear, in part because no rapid assay is available for measuring the changes in Pol II pausing
144                     Although many structures are available for members of this family, none exhibits
145 lonization capacity when glucose or fructose is available for metabolism.
146                    Ninety manual annotations were available for model training and validation.
147 solid-state structures, however, few options are available for modifying their outer pores to impart
148 llenging problem, as few rational approaches are available for modulating the reactivity of this spec
149  cumulative follow-up, mortality information was available for more than 98%.
150 imited by sample availability, but sequences were available for more than 40% of diagnoses.
151 mic case studies where comparable phenotypes were available for mouse and human inflammatory diseases
152 ple comprised 3641 PWID; data from 2712 PWID were available for multivariate analysis after further r
153                      However, no information is available for NSAID-induced urticarial/angioedema (NI
154 etermined as sufficiently low and the animal is available for observation.
155 creased for all items when prior information was available for one of the items.
156  is not surprising that neuroanatomical data are available for only one genus within the group-Pleuro
157 iseases, good coverage of their interactions is available for only a fraction of the 535 human kinase
158                Because genotypic information was available for only 257 hybrids, we used the genomic
159 al condition, radiologic response assessment was available for only 46 of the 50 patients.
160 large scale differential binding sites (DBS) were available for only H3K4me3 in the susceptible culti
161 eveloping fetus and only limited safety data are available for others.
162 erfaces, whilst ensuring the latest versions are available for our users.
163 als and 7461 end-stage kidney disease events were available for our primary outcome analysis.
164                            Effective options are available for patients who may be pregnant, those wh
165       Finally, we review the treatments that are available for patients with CPVT, their efficacy, an
166 rtality for which only palliative treatments are available for patients with late-stage disease.
167                     Few effective treatments are available for patients with metastatic MCC.
168 nd in some populations, but limited evidence is available for positive longer-term outcomes and for e
169          No satisfactory canonical treatment is available for post-kala-azar dermal leishmaniasis (PK
170 lly evaluated using the DeltaSUV(max) method were available for post hoc assessment of the Deauville
171                                 Limited data are available for pregnant women with COVID-19 pneumonia
172           Of these participants, 819 (84.8%) were available for primary outcome analysis at 6-month f
173 05 stations-a significantly larger pool than was available for prior studies.
174 nd 1,192,414 single-nucleotide polymorphisms were available for PRS-analyses.
175 e license and all datasets used in the paper are available for public download.
176                                   MetaHipMer is available for public use under an open source license
177                               spectrum_utils is available for Python 3.6+, includes extensive online
178 s Rab6-dependent pool of recycled MR1, which is available for reloading with ligands from bacterial p
179 atching epigenomic developmental matrix, and are available for researchers to further mine and integr
180                            However, only few are available for routine diagnosis, and many are restri
181 ipheral artery disease; however, no solution is available for safe and reliable use in the tortuous v
182    Even though a number of methods and tools are available for sample size calculation for microarray
183 sepsis and 28 of the bypass surgery subjects were available for screening with an aptamer-based prote
184                          Fifty-five patients were available for statistical analysis (test group, n =
185 alth by affecting the behavioural roles that are available for students to perform, the resources ava
186                         Now, RNA-seq methods are available for studying many different aspects of RNA
187                Hitherto, no animal model has been available for studying in vivo the pathogenicity of
188 ch discussions, an adequate body of evidence is available for support, and patients are generally rec
189 tage, so 2039 and 2093 patients respectively were available for survival analysis.
190 imen types for each test?" and "What options are available for T. pallidum molecular epidemiology?" T
191 specially when only limited clinical samples are available for testing, and the importance of a multi
192 ers of disease outbreak when no STEC isolate is available for testing.
193                                  Few methods are available for the catalytic activation of hydroxy fu
194 munoprecipitation and sequencing (MeRIP-seq) are available for the detection of mRNA modifications.
195                             Accurate methods are available for the investigation of other neurodegene
196          Several effective treatment options are available for the most common types of UI (stress, u
197                         Myriad interventions are available for the treatment of actinic keratosis loc
198 Currently, no FDA approved drugs or vaccines are available for the treatment of LASV fever.
199 c agonists and antagonists of catecholamines are available for the treatment of some disorders.
200  particular, in detection, evidence can only be available for the presence, not the absence, of a tar
201 on and immunoprecipitation experiments, will be available for the same samples.
202              To date, no reliable tools have been available for the meta-analysis of surface-based mo
203 an organized pedigree visualization platform is available for the accessions and cultivars in rice br
204 vel viruses in NGS data, no appropriate tool is available for the classification and identification o
205                           Little information is available for the determination of glucose within glu
206 3.6% to 11% of the total Fe in the sediments was available for the reduction of DNAN and its partiall
207                     Four hundred twelve eyes were available for the analyses.
208                   Data from 136 participants were available for the intention-to-treat analysis of th
209 nmeasured confounding and no laboratory data were available for the majority of patients, and molecul
210              Data from 89 evaluable patients were available for the purpose of analysis comprising an
211 e their utility few simple catalytic methods are available for their synthesis in high enantiopurity.
212 bioactive molecules, and a number of methods are available for their synthesis.
213                             What information is available for them?
214                        No specific therapies are available for these abnormalities.
215 cleotide short tandem repeat (diSTR) markers are available for this and similar purposes, they have c
216    Currently, no disease-modifying therapies are available for this group of disorders.
217                             While programmes are available for this, there is a need for a real-time
218 ffects, Tumor Response Supplemental material is available for this article.
219                        Supplemental material is available for this article.
220  (C) RSNA, 2019 Online supplemental material is available for this article.
221  (C) RSNA, 2020 Online supplemental material is available for this article.
222     Graphical Abstract: A graphical abstract is available for this article.
223 ts, Oncology, Pancreas Supplemental material is available for this article.
224         (C) RSNA, 2020 Supplemental material is available for this article.
225           Visual Overview: A visual overview is available for this article.
226        Graphic Abstract: An graphic abstract is available for this article.
227         Graphic Abstract: A graphic abstract is available for this article.
228            Visual Overview A visual overview is available for this article.
229  (C) RSNA, 2021 Online supplemental material is available for this article.
230  (C) RSNA, 2018 Online supplemental material is available for this article.
231   (C)RSNA, 2019 Online supplemental material is available for this article.
232 s.Visual Overview: An online visual overview is available for this article.
233 Graphic Abstract: An online graphic abstract is available for this article.
234 y.(C) RSNA, 2019Online supplemental material is available for this article.
235   Visual Overview: An online visual overview is available for this article.
236 ping sequence at 1.5 T.Supplemental material is available for this article.(C) RSNA, 2020.
237 with synthetic lesions.Supplemental material is available for this article.(C) RSNA, 2020.
238 d attending physicians.Supplemental material is available for this article.(C) RSNA, 2020.
239 mmon and rare diseases.Supplemental material is available for this article.(C) RSNA, 2020.
240 monia is nonnegligible.Supplemental material is available for this article.(C) RSNA, 2020.
241 f PE risk and severity.Supplemental material is available for this article.(C) RSNA, 2020.
242 ers in lethal COVID-19.Supplemental material is available for this article.(C) RSNA, 2020.
243 linical staging of MPM.Supplemental material is available for this article.(C) RSNA, 2020.
244 -Quantitative, PancreasSupplemental material is available for this article.(C) RSNA, 2020.
245 etection of MVI in HCC.Supplemental material is available for this article.(C) RSNA, 2020.
246 ctional image analysis.Supplemental material is available for this article.(C) RSNA, 2020.
247 ghted Imaging, OncologySupplemental material is available for this article.(C) RSNA, 2020.
248 s with SSc-related ILD.Supplemental material is available for this article.(C) RSNA, 2020.
249 rger training datasets.Supplemental material is available for this article.(C) RSNA, 2020.
250 ans demonstrating iNPH.Supplemental material is available for this article.(C) RSNA, 2020.
251 lying vascular process.Supplemental material is available for this article.(C) RSNA, 2020.
252 ith the proposed DCNet.Supplemental material is available for this article.(C) RSNA, 2020.
253  of 1280 x 1024 pixels.Supplemental material is available for this article.(C) RSNA, 2020.
254 eproductive, UltrasoundSupplemental material is available for this article.(C) RSNA, 2020.
255 e to radiation from CT.Supplemental material is available for this article.(C) RSNA, 2020.
256 out airway obstruction.Supplemental material is available for this article.(C) RSNA, 2020.
257  reconstructed volumes.Supplemental material is available for this article.(C) RSNA, 2020.
258 f neurologic disorders.Supplemental material is available for this article.(C) RSNA, 2020.
259 he content in the MIPs.Supplemental material is available for this article.(C) RSNA, 2020.
260 nd risk stratification.Supplemental material is available for this article.(C) RSNA, 2020.
261 evere MV regurgitation.Supplemental material is available for this article.(C) RSNA, 2020.
262 es outcome predictions.Supplemental material is available for this article.(C) RSNA, 2020.
263 ve Studies, Large BowelSupplemental material is available for this article.(C) RSNA, 2020.
264 vasive CAD diagnostics.Supplemental material is available for this article.(C) RSNA, 2020.
265 oth anatomic locations.Supplemental material is available for this article.(C) RSNA, 2020.
266 intraobserver analyses.Supplemental material is available for this article.(C) RSNA, 2020.
267  the COVID-19 pandemic.Supplemental material is available for this article.(C) RSNA, 2020.
268 al, MR-Imaging, UrinarySupplemental material is available for this article.(C) RSNA, 2020.
269 d paravalvular leakage.Supplemental material is available for this article.(C) RSNA, 2020.
270 e acute safety profile.Supplemental material is available for this article.(C) RSNA, 2020.
271 splenic volume changes.Supplemental material is available for this article.(C) RSNA, 2020.
272 ch to estimate E/E (m).Supplemental material is available for this article.(C) RSNA, 2020.
273 longing their workflow.Supplemental material is available for this article.(C) RSNA, 2020.
274 ate clinical workflows.Supplemental material is available for this article.(C) RSNA, 2020See also com
275 ation of immunotherapy.Supplemental material is available for this article.(C) RSNA, 2020See also the
276 erences in acquisition.Supplemental material is available for this article.(C) RSNA, 2020See also the
277 s used to perform them.Supplemental material is available for this article.(C) RSNA, 2020See also the
278  pediatric populations.Supplemental material is available for this article.(C) RSNA, 2020See also the
279 by using few SM images.Supplemental material is available for this article.Published under a CC BY 4.
280 and site-specific data.Supplemental material is available for this article.Published under a CC BY 4.
281 adult patients with CF.Supplemental material is available for this article.See also the commentary by
282 ets and trained models.Supplemental material is available for this article.See also the commentary by
283 ysis, Prostate, StagingSupplemental material is available for this article.See also the commentary by
284 invasive PH evaluation.Supplemental material is available for this article.See also the commentary by
285 d.(C) RSNA, 2020Online supplemental material is available for this article.See also the editorial by
286 s.(C) RSNA, 2020Online supplemental material is available for this article.See also the editorial by
287 s.(C) RSNA, 2020Online supplemental material is available for this article.See also the editorial by
288 e.(C) RSNA, 2019Online supplemental material is available for this article.See also the editorial by
289 s.(C) RSNA, 2019Online supplemental material is available for this article.See also the editorial by
290 d.(C) RSNA, 2019Online supplemental material is available for this article.See also the editorial by
291 h.(C) RSNA, 2019Online supplemental material is available for this article.See also the editorial by
292 g.(C) RSNA, 2020Online supplemental material is available for this article.See also the editorial by
293 d.(C) RSNA, 2019Online supplemental material is available for this article.See also the editorial by
294  Limited genotype by environment information is available for traits valued by consumers.
295                       A subgroup of patients was available for tryptase genotyping.
296                   A total of 10 patients who were available for tryptase genotyping were all confirme
297    At present, no approved pharmacotherapies are available for unclassifiable interstitial lung disea
298 how much light and thus how much information is available for visual processing.
299 s the retina and, thus, how much information is available for visual processing.
300                               Where evidence is available for y-ome genes, it most often points to th

 
Page Top